Hanmi Pharmaceutical Earnings Beat Expectations – What Drives the Rally? Hanmi Pharmaceutical is rated Buy: revenue +29.3% YoY, gross margin 59.6%, net income +115.2% YoY, but operating profit -36.0% YoY and China receivables governance risk remain. Valuation below average target. 2026년 09월 21일 English
Hanmi Pharmaceutical Earnings Strength Signals Obesity Growth Hanmi Pharmaceutical is rated Buy as strong revenue and 59.6% gross margin offset a 36% YoY operating profit drop; investors bet execution and partnerships will stabilize operating earnings. 2026년 09월 08일 English
Hanmi Pharmaceutical Stock Resilient Despite Profit Dip: Key Insight Hanmi Pharmaceutical stock is discounted by governance and K-bio sentiment, but earnings remain resilient with net income up 6.8% YoY; analysts see Buy with 51% upside to the 624,615 won average target. 2026년 07월 09일 English
Hanmi Pharmaceutical Stock Pops on GLP 2 News – What Earnings Show Hanmi Pharmaceutical shares rallied on Eli Lilly tech transfer headlines, but latest results show flat revenue and falling operating profit (-9.1% YoY). Bulls cite retained Korea rights and net profit stability; bears warn margins may not recover fast enough to justify the premium valuation. 2026년 06월 05일 English
